Salarius
SLRX

股本结构

单位：万股
公告日期 2025-11-14 2025-10-21 2025-09-26 2025-09-23 2025-08-22 2025-08-14
证券总股本 586.22 105.18 94.45 93.80 50.96 50.90
普通股本 586.22 105.18 94.45 93.80 50.96 50.90
优先股 未披露 未披露 未披露 未披露 未披露 未披露
其他 未披露 未披露 未披露 未披露 未披露 未披露
变动日期 2025-11-12 2025-10-10 2025-09-26 2025-09-19 2025-08-22 2025-08-18
注释：中概股证券总股本=普通股股本/ 存托凭证比例

历史变动

公告日期 变动后普通股本（万股） 变动后优先股（万股） 变动原因 变动日期
2025-11-14 586.22 未披露
更多>>
Common Stock offered 2,514,335 shares by the company
2025-11-12
2025-10-21 105.18 未披露 定期报告 2025-10-10
2025-09-26 94.45 未披露 定期报告 2025-09-26
2025-09-23 93.80 未披露 定期报告 2025-09-19
2025-08-22 50.96 未披露 定期报告 2025-08-22
2025-08-14 50.90 未披露
更多>>
a 1-for-15 reverse stock split of its common stock
2025-08-18
2025-08-14 760.00 未披露 定期报告 2025-08-14
2025-08-12 764.56 未披露 定期报告 2025-08-11
2025-08-12 212.73 未披露
更多>>
From March 31, 2025 to June 30, 2025 Issuance of equity securities, net
2025-06-30
2025-04-17 212.73 未披露 定期报告 2025-04-11
2025-05-14 208.18 未披露
更多>>
From December 31, 2024 to March 31, 2025 Issuance of equity securities, net
2025-03-31
2025-03-21 174.57 未披露 定期报告 2025-03-17
2025-03-11 172.80 未披露 定期报告 2025-03-07
2025-01-17 158.36 未披露
更多>>
On January 13, 2025 the Company issued 142,410 common shares
2025-01-13
2024-11-14 144.12 未披露
更多>>
From June 30, 2024 to September 30, 2024 Issuance of equity securities, net
2024-09-30
2024-08-09 144.12 未披露 定期报告 2024-08-07
2024-08-09 64.12 未披露
更多>>
From March 31, 2024 to June 30, 2024 Issuance of equity securities and other, net
2024-06-30
2024-06-12 60.00 未披露
更多>>
1-for-8 Reverse Stock Split
2024-06-17
2024-06-12 470.00 未披露 定期报告 2024-06-12
2024-04-22 477.64 未披露 定期报告 2024-04-16
2024-05-13 431.44 未披露
更多>>
From December 31, 2023 to March 31, 2024 Issuance of equity securities, net
2024-03-31
2024-03-26 431.44 未披露 定期报告 2024-03-12
2023-11-09 393.84 未披露
更多>>
From June 30, 2023 to September 30, 2023 Issuance of equity securities, net
2023-09-30
2023-08-10 364.14 未披露 定期报告 2023-08-07
2023-08-10 335.21 未披露
更多>>
From March 31, 2023 to June 30, 2023 Issuance of equity securities, net
2023-06-30
2023-05-26 335.21 未披露 定期报告 2023-05-18
2023-05-11 249.14 未披露 定期报告 2023-05-05
2023-05-01 246.89 未披露 定期报告 2023-04-21
2023-05-11 246.83 未披露
更多>>
From December 31, 2022 to March 31, 2023 Equity-based compensation expense Issuance of equity securities, net
2023-03-31
2023-03-27 246.80 未披露 定期报告 2023-03-20
2023-03-27 225.59 未披露
更多>>
From December 31, 2021 to December 31, 2022 Common Stock issued for in-process research and development technology Issuance of equity securities, net Equity-based compensation expense Issuance of equity securities for services
2022-12-31
2022-11-10 227.82 未披露 定期报告 2022-11-07
2022-10-14 224.90 未披露
更多>>
Salarius Pharmaceuticals Announces 1-for-25 Reverse Stock Split.
2022-10-17
2022-10-14 5623.60 未披露 定期报告 2022-10-14
2022-08-05 5611.62 未披露
更多>>
From March 31, 2022 to June 30, 2022 Equity-based compensation expense Issuance of equity securities, net
2022-06-30
2022-05-12 5611.62 未披露 定期报告 2022-05-09
2022-04-26 5603.66 未披露
更多>>
1.Common stock offered by 9,339,436 shares of Common Stock. 2.Unless otherwise indicated, the number of shares of common stock to be outstanding immediately after this offering is based on 45,241,808 shares outstanding as of December 31, 2021.
2022-04-26
2022-05-12 4669.72 未披露
更多>>
From December 31, 2021 to March 31, 2022 Common stock issued for in-process research and development technology Equity-based compensation expense
2022-03-31
2022-03-25 4669.72 未披露 定期报告 2022-03-18
2022-03-25 4524.18 未披露
更多>>
From December 31, 2020 to December 31, 2021 Issuance of equity securities, net Warrants exercised for cash Equity-based compensation expense Issuance of equity securities for services
2021-12-31
2021-11-04 4520.61 未披露 定期报告 2021-11-01
2021-11-04 4517.25 未披露
更多>>
From June 30, 2021 to September 30, 2021 Issuance of equity securities, net
2021-09-30
2021-08-05 4477.88 未披露
更多>>
From March 31, 2021 to June 30, 2021 Equity-based compensation expense Equity-based services expense
2021-06-30
2021-05-12 4477.26 未披露 定期报告 2021-05-10
2021-05-12 4473.43 未披露
更多>>
From December 31, 2020 to March 31, 2021 Issuance of equity securities, net Warrants exercised for cash, net
2021-03-31
2021-03-18 4473.43 未披露 定期报告 2021-03-15
2021-03-08 4246.94 未披露
更多>>
1.Common stock offered by the company 14,614,541 shares. 2.The number of shares of common stock to be outstanding immediately after this offering is based on 27,854,867 shares outstanding as of February 28, 2021.
2021-03-08
2021-03-03 2785.49 未披露 定期报告 2021-02-28
2021-03-18 2380.85 未披露
更多>>
from December 31, 2019 to December 31, 2020 Issuance of equity securities, net Preferred shares converted to common shares Warrants exercised for cash Equity-based compensation expense Issuance of equity securities for services
2020-12-31
2020-11-12 1984.39 未披露 定期报告 2020-11-09
2020-11-12 1981.89 未披露
更多>>
From June 30, 2020 to September 30, 2020 Warrants exercised for cash Issuance of equity securities, net Equity-based compensation expense
2020-09-30
2020-08-12 1982.04 未披露 定期报告 2020-08-07
2020-08-03 1810.69 未披露
更多>>
1.Common stock offered by the company 4,461,209 shares. 2.The number of shares of common stock to be outstanding immediately after this offering is based on 13,645,677 shares outstanding as of March 31, 2020.
2020-08-03
2020-07-29 1464.00 未披露 定期报告 2020-07-28
2020-08-12 1463.80 未披露
更多>>
From March 31, 2020 to June 30, 2020 Preferred shares converted to common shares Equity-based compensation expense Equity-based services expense
2020-06-30
2020-05-14 1365.08 未披露 定期报告 2020-05-05
2020-04-29 1367.12 未披露 定期报告 2020-04-22
2020-05-14 1364.57 46.87
更多>>
From December 31, 2019 to March 31, 2020 Issuance of equity securities, net Preferred shares converted to common shares Equity-based compensation expense
2020-03-31
2020-03-23 1366.65 未披露 定期报告 2020-03-16
2020-03-23 451.12 未披露
更多>>
from December 31, 2018 to December 31, 2019 Issuance of equity securities, net Issuance of equity securities for license, net Equity-based compensation expense Effect of reverse acquisition
2019-12-31
2019-11-12 406.85 未披露 定期报告 2019-11-11
2019-11-12 375.62 未披露
更多>>
from June 30, 2019 to September 30, 2019 Effect of reverse acquisition Equity-based compensation expense
2019-09-30
2019-09-18 374.72 未披露 定期报告 2019-09-11
2019-09-18 374.72 未披露 定期报告 2019-08-31
2019-07-22 72.28 未披露
更多>>
On July 19, 2019, in connection with, and prior to the completion of, the Merger, the Registrant effected a 1-for-25 reverse stock split of its then outstanding common stock (the “Reverse Split”) and the Registrant changed its name to “Salarius Pharmaceuticals, Inc.” (the “Name Change”), pursuant to an amendment to its certificate of incorporation filed with the Secretary of State of the State of Delaware on July 18, 2019, which became effective on July 19, 2019.
2019-07-22
2019-07-17 1806.95 未披露 定期报告 2019-07-12
2019-07-17 1806.86 未披露
更多>>
from March 31, 2019 to June 30, 2019 Vesting of restricted common stock
2019-06-30
2019-04-18 1806.95 未披露 定期报告 2019-04-01
2019-05-01 1806.80 未披露
更多>>
from December 31, 2018 to March 31, 2019 Vesting of restricted common stock
2019-03-31
2019-03-26 1806.95 未披露 定期报告 2019-02-28
2019-03-06 1806.74 未披露
更多>>
from December 31, 2017 to December 31, 2018 Vesting of restricted common stock Issuance of common stock from option exercises
2018-12-31
2018-11-05 1806.95 未披露 定期报告 2018-10-31
2018-11-05 1806.68 未披露 定期报告 2018-09-30
2018-08-01 1806.95 未披露 定期报告 2018-07-27
2018-08-01 1806.61 未披露 定期报告 2018-06-30
2018-05-02 1801.35 未披露 定期报告 2018-04-27
2018-04-23 1798.48 未披露 定期报告 2018-04-11
2018-05-02 1798.09 未披露 定期报告 2018-03-31
2018-03-07 1797.22 未披露 定期报告 2018-03-02
2018-03-07 1779.72 未披露
更多>>
from December 31, 2016 to December 31, 2017 Vesting of restricted common stock Issuance of common stock from option exercises
2017-12-31
2017-11-06 1797.18 未披露 定期报告 2017-11-03
2017-11-06 1754.14 未披露 定期报告 2017-09-30
2017-08-02 1797.18 未披露 定期报告 2017-07-28
2017-08-02 1728.59 未披露 定期报告 2017-06-30
2017-05-03 1797.06 未披露 定期报告 2017-04-28
2017-05-03 1702.92 未披露 定期报告 2017-03-31
2017-03-08 1797.06 未披露 定期报告 2017-03-03
2017-03-08 1677.38 未披露
更多>>
from December 31, 2015 to December 31, 2016 Vesting of restricted common stock Issuance of common stock from option exercises
2016-12-31
2016-11-02 1797.06 未披露 定期报告 2016-10-28
2016-11-02 1651.83 未披露 定期报告 2016-09-30
2016-08-03 1796.85 未披露 定期报告 2016-07-29
2016-08-03 1626.08 未披露 定期报告 2016-06-30
2016-04-28 1796.79 未披露 定期报告 2016-04-11
2016-05-04 1600.47 未披露 定期报告 2016-03-31
2016-03-18 1795.68 未披露 定期报告 2016-03-17
2016-03-08 1795.48 未披露 定期报告 2016-03-04
2016-03-08 1574.16 未披露
更多>>
from December 31, 2014 to December 31, 2015 Conversion of Series A convertible preferred stock to common stock Conversion of Series B convertible preferred stock to common stock IPO proceeds, net of offering costs of $7,998,871 Vesting of restricted common stock Issuance of common stock from option exercises In January 2015, the Company effected a one-for-4.2825 reverse stock split of its then issued and outstanding common stock.
2015-12-31
2015-11-04 1794.39 未披露 定期报告 2015-10-30
2015-11-04 1544.93 未披露 定期报告 2015-09-30
2015-08-05 1793.83 未披露 定期报告 2015-07-31
2015-08-05 1519.09 未披露 定期报告 2015-06-30
2015-05-06 1793.48 未披露 定期报告 2015-04-30
2015-05-06 1493.21 未披露 定期报告 2015-03-31
2015-03-24 1793.37 未披露 定期报告 2015-03-20
2015-01-29 1780.54 未披露
更多>>
the conversion of all our outstanding convertible preferred stock into an aggregate of 6,971,108 shares of common stock, including shares of our series B convertible preferred stock issued after September 30, 2014; a one-for-4.2825 reverse stock split of our common stock and a proportional adjustment to the existing conversion ratio of each series of our convertible preferred stock, which became effective on January 15, 2015;
2015-01-29
2015-01-20 1240.54 2902.41
更多>>
a one-for-4.2825 reverse stock split of our common stock and a proportional adjustment to the existing conversion ratio of each series of our convertible preferred stock, which became effective on January 15, 2015;
2015-01-16
2015-03-24 221.57 2985.39
更多>>
from February 26, 2014 to December 31, 2014 Issuance of Series A convertible preferred stock, net of issuance costs of $138,189 Issuance of Series B convertible preferred stock, net of issuance costs of $55,835 Vesting of restricted common stock Issuance of common stock from option exercises
2014-12-31
2014-12-29 839.07 2902.41
更多>>
from February 26, 2014 to September 30, 2014 Issuance of Series A convertible preferred stock, net of issuance costs of $138,189 Issuance of Series B convertible preferred stock, net of issuance costs of $54,060 Vesting of restricted common stock Issuance of common stock from option exercises
2014-09-30
Common Stock offered 2,514,335 shares by the company
a 1-for-15 reverse stock split of its common stock
From March 31, 2025 to June 30, 2025 Issuance of equity securities, net
From December 31, 2024 to March 31, 2025 Issuance of equity securities, net
On January 13, 2025 the Company issued 142,410 common shares
From June 30, 2024 to September 30, 2024 Issuance of equity securities, net
From March 31, 2024 to June 30, 2024 Issuance of equity securities and other, net
1-for-8 Reverse Stock Split
From December 31, 2023 to March 31, 2024 Issuance of equity securities, net
From June 30, 2023 to September 30, 2023 Issuance of equity securities, net
From March 31, 2023 to June 30, 2023 Issuance of equity securities, net
From December 31, 2022 to March 31, 2023 Equity-based compensation expense Issuance of equity securities, net
From December 31, 2021 to December 31, 2022 Common Stock issued for in-process research and development technology Issuance of equity securities, net Equity-based compensation expense Issuance of equity securities for services
Salarius Pharmaceuticals Announces 1-for-25 Reverse Stock Split.
From March 31, 2022 to June 30, 2022 Equity-based compensation expense Issuance of equity securities, net
1.Common stock offered by 9,339,436 shares of Common Stock. 2.Unless otherwise indicated, the number of shares of common stock to be outstanding immediately after this offering is based on 45,241,808 shares outstanding as of December 31, 2021.
From December 31, 2021 to March 31, 2022 Common stock issued for in-process research and development technology Equity-based compensation expense
From December 31, 2020 to December 31, 2021 Issuance of equity securities, net Warrants exercised for cash Equity-based compensation expense Issuance of equity securities for services
From June 30, 2021 to September 30, 2021 Issuance of equity securities, net
From March 31, 2021 to June 30, 2021 Equity-based compensation expense Equity-based services expense
From December 31, 2020 to March 31, 2021 Issuance of equity securities, net Warrants exercised for cash, net
1.Common stock offered by the company 14,614,541 shares. 2.The number of shares of common stock to be outstanding immediately after this offering is based on 27,854,867 shares outstanding as of February 28, 2021.
from December 31, 2019 to December 31, 2020 Issuance of equity securities, net Preferred shares converted to common shares Warrants exercised for cash Equity-based compensation expense Issuance of equity securities for services
From June 30, 2020 to September 30, 2020 Warrants exercised for cash Issuance of equity securities, net Equity-based compensation expense
1.Common stock offered by the company 4,461,209 shares. 2.The number of shares of common stock to be outstanding immediately after this offering is based on 13,645,677 shares outstanding as of March 31, 2020.
From March 31, 2020 to June 30, 2020 Preferred shares converted to common shares Equity-based compensation expense Equity-based services expense
From December 31, 2019 to March 31, 2020 Issuance of equity securities, net Preferred shares converted to common shares Equity-based compensation expense
from December 31, 2018 to December 31, 2019 Issuance of equity securities, net Issuance of equity securities for license, net Equity-based compensation expense Effect of reverse acquisition
from June 30, 2019 to September 30, 2019 Effect of reverse acquisition Equity-based compensation expense
On July 19, 2019, in connection with, and prior to the completion of, the Merger, the Registrant effected a 1-for-25 reverse stock split of its then outstanding common stock (the “Reverse Split”) and the Registrant changed its name to “Salarius Pharmaceuticals, Inc.” (the “Name Change”), pursuant to an amendment to its certificate of incorporation filed with the Secretary of State of the State of Delaware on July 18, 2019, which became effective on July 19, 2019.
from March 31, 2019 to June 30, 2019 Vesting of restricted common stock
from December 31, 2018 to March 31, 2019 Vesting of restricted common stock
from December 31, 2017 to December 31, 2018 Vesting of restricted common stock Issuance of common stock from option exercises
from December 31, 2016 to December 31, 2017 Vesting of restricted common stock Issuance of common stock from option exercises
from December 31, 2015 to December 31, 2016 Vesting of restricted common stock Issuance of common stock from option exercises
from December 31, 2014 to December 31, 2015 Conversion of Series A convertible preferred stock to common stock Conversion of Series B convertible preferred stock to common stock IPO proceeds, net of offering costs of $7,998,871 Vesting of restricted common stock Issuance of common stock from option exercises In January 2015, the Company effected a one-for-4.2825 reverse stock split of its then issued and outstanding common stock.
the conversion of all our outstanding convertible preferred stock into an aggregate of 6,971,108 shares of common stock, including shares of our series B convertible preferred stock issued after September 30, 2014; a one-for-4.2825 reverse stock split of our common stock and a proportional adjustment to the existing conversion ratio of each series of our convertible preferred stock, which became effective on January 15, 2015;
a one-for-4.2825 reverse stock split of our common stock and a proportional adjustment to the existing conversion ratio of each series of our convertible preferred stock, which became effective on January 15, 2015;
from February 26, 2014 to December 31, 2014 Issuance of Series A convertible preferred stock, net of issuance costs of $138,189 Issuance of Series B convertible preferred stock, net of issuance costs of $55,835 Vesting of restricted common stock Issuance of common stock from option exercises
from February 26, 2014 to September 30, 2014 Issuance of Series A convertible preferred stock, net of issuance costs of $138,189 Issuance of Series B convertible preferred stock, net of issuance costs of $54,060 Vesting of restricted common stock Issuance of common stock from option exercises
同花顺个股页面 | 模拟炒股 | 股民学校 | 手机炒股| 联系我们

免责声明:本信息由同花顺金融研究中心提供，仅供参考，同花顺金融研究中心力求但不保证数据的完全准确，如有错漏请以中国证监会指定上市公司信息披露媒体为准，同花顺金融研究中心不对因该资料全部或部分内容而引致的盈亏承担任何责任。用户个人对服务的使用承担风险。同花顺对此不作任何类型的担保。同花顺不担保服务一定能满足用户的要求，也不担保服务不会受中断，对服务的及时性，安全性，出错发生都不作担保。同花顺对在同花顺上得到的任何信息服务或交易进程不作担保。同花顺提供的包括同花顺理财的所有文章，数据，不构成任何的投资建议，用户查看或依据这些内容所进行的任何行为造成的风险和结果都自行负责，与同花顺无关。

【免责声明】本产品中的行情数据及资讯信息来源于第三方，长江证券不对收集数据的版权、真实性、准确性及传输过程中发生的传送错误承担法律责任。本内容仅供参考，不作为投资决策依据，长江证券不对因据此操作产生的盈亏承担任何责任。投资有风险，入市需谨慎。